Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14559651 | 0.82 | EPHX2 (0.38) | KMT2AL3MBTL1GAAALDH1A1MAPT | |
| SCHEMBL6377834 | 0.78 | ALDH1A1 (0.36) | KMT2AL3MBTL1GAAALDH1A1MAPT | |
| SCHEMBL6377829 | 0.78 | ALDH1A1 (0.36) | KMT2AL3MBTL1GAAALDH1A1MAPT | |
| SCHEMBL9209379 | 0.76 | GAA (0.41) | KMT2AL3MBTL1GAAALDH1A1MAPT | |
| SCHEMBL6425669 | 0.74 | ALDH1A1 (0.36) | KMT2AL3MBTL1GAAALDH1A1MAPT | |
| SCHEMBL6425668 | 0.74 | ALDH1A1 (0.36) | KMT2AL3MBTL1GAAALDH1A1MAPT | |
| SCHEMBL6381421 | 0.73 | ALDH1A1 (0.43) | KMT2AL3MBTL1GAAALDH1A1MAPT | |
| SCHEMBL6381415 | 0.73 | ALDH1A1 (0.43) | KMT2AL3MBTL1GAAALDH1A1MAPT | |
| SCHEMBL1978033 | 0.72 | ALDH1A1 (0.39) | KMT2AL3MBTL1GAAALDH1A1MAPT | |
| SCHEMBL3910882 | 0.72 | ALDH1A1 (0.41) | KMT2AL3MBTL1GAAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937267-A4 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-08-26 | — | — | EP | disclosed |
| EP-1937230-A4 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-08-26 | — | — | EP | disclosed |
| US-20080275079-A1 | 3-Endo)-3-[2,2-Bis-(3-hydroxy-phenyl)-ethenyl]-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane bromide; chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, allergic rhinitis | GLAXO GROUP LIMITED | 2008-11-06 | — | — | US | disclosed |
| US-20080234315-A1 | M3 Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-09-25 | — | — | US | disclosed |
| EP-1937230-A2 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-07-02 | — | — | EP | disclosed |
| EP-1937267-A2 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007016650-A2 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016639-A2 | M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234315-A1 | M3 Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRM2, CHRM1 | KMT2A 1936/4885L3MBTL1 1642/4885GAA 4767/4885 |
| US-20080275079-A1 | 3-Endo)-3-[2,2-Bis-(3-hydroxy-phenyl)-ethenyl]-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane bromide; chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, allergic rhinitis | CHRM3, EDNRB, BDKRB2 | KMT2A 2752/4885L3MBTL1 3600/4885GAA 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.